NASDAQ:CORT

Corcept Therapeutics Competitors

$22.68
-0.23 (-1.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.24
Now: $22.68
$22.82
50-Day Range
$22.91
MA: $25.01
$26.94
52-Week Range
$11.57
Now: $22.68
$31.18
Volume557,546 shs
Average Volume590,172 shs
Market Capitalization$2.66 billion
P/E Ratio25.48
Dividend YieldN/A
Beta1.04

Competitors

Corcept Therapeutics (NASDAQ:CORT) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying CORT stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Corcept Therapeutics, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Corcept Therapeutics (NASDAQ:CORT) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Valuation & Earnings

This table compares Corcept Therapeutics and Johnson & Johnson's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$306.49 million8.68$94.18 million$0.7729.45
Johnson & Johnson$82.06 billion5.17$15.12 billion$8.6818.58

Johnson & Johnson has higher revenue and earnings than Corcept Therapeutics. Johnson & Johnson is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Corcept Therapeutics and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corcept Therapeutics30.73%25.38%23.16%
Johnson & Johnson21.01%34.64%13.40%

Insider & Institutional Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Corcept Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Corcept Therapeutics and Johnson & Johnson, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corcept Therapeutics01102.50
Johnson & Johnson031102.79

Corcept Therapeutics presently has a consensus target price of $24.00, suggesting a potential upside of 5.82%. Johnson & Johnson has a consensus target price of $180.6429, suggesting a potential upside of 12.03%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Corcept Therapeutics.

Corcept Therapeutics (NASDAQ:CORT) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Corcept Therapeutics and Pfizer's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$306.49 million8.68$94.18 million$0.7729.45
Pfizer$51.75 billion3.94$16.27 billion$2.9512.41

Pfizer has higher revenue and earnings than Corcept Therapeutics. Pfizer is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Corcept Therapeutics and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corcept Therapeutics30.73%25.38%23.16%
Pfizer17.85%24.88%9.32%

Insider & Institutional Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 67.4% of Pfizer shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Corcept Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Corcept Therapeutics and Pfizer, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corcept Therapeutics01102.50
Pfizer010302.23

Corcept Therapeutics currently has a consensus price target of $24.00, suggesting a potential upside of 5.82%. Pfizer has a consensus price target of $38.5714, suggesting a potential upside of 5.39%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Corcept Therapeutics is more favorable than Pfizer.

Summary

Corcept Therapeutics beats Pfizer on 10 of the 14 factors compared between the two stocks.

Corcept Therapeutics (NASDAQ:CORT) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Corcept Therapeutics and Merck & Co., Inc.'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$306.49 million8.68$94.18 million$0.7729.45
Merck & Co., Inc.$46.84 billion4.12$9.84 billion$5.1914.70

Merck & Co., Inc. has higher revenue and earnings than Corcept Therapeutics. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Corcept Therapeutics and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corcept Therapeutics30.73%25.38%23.16%
Merck & Co., Inc.24.33%53.83%16.83%

Insider & Institutional Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Corcept Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Corcept Therapeutics and Merck & Co., Inc., as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corcept Therapeutics01102.50
Merck & Co., Inc.021202.86

Corcept Therapeutics currently has a consensus price target of $24.00, suggesting a potential upside of 5.82%. Merck & Co., Inc. has a consensus price target of $95.9167, suggesting a potential upside of 25.69%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts plainly believe Merck & Co., Inc. is more favorable than Corcept Therapeutics.

Corcept Therapeutics (NASDAQ:CORT) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Corcept Therapeutics and AbbVie's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$306.49 million8.68$94.18 million$0.7729.45
AbbVie$33.27 billion5.71$7.88 billion$8.9412.03

AbbVie has higher revenue and earnings than Corcept Therapeutics. AbbVie is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Corcept Therapeutics and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corcept Therapeutics30.73%25.38%23.16%
AbbVie18.16%439.24%13.22%

Insider & Institutional Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of AbbVie shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Corcept Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Corcept Therapeutics and AbbVie, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corcept Therapeutics01102.50
AbbVie121402.76

Corcept Therapeutics currently has a consensus price target of $24.00, suggesting a potential upside of 5.82%. AbbVie has a consensus price target of $115.75, suggesting a potential upside of 7.63%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Corcept Therapeutics.

Eli Lilly and (NYSE:LLY) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability.

Insider and Institutional Ownership

75.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 75.4% of Corcept Therapeutics shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 16.4% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Eli Lilly and and Corcept Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and041102.73
Corcept Therapeutics01102.50

Eli Lilly and currently has a consensus price target of $196.40, suggesting a potential upside of 6.46%. Corcept Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 5.82%. Given Eli Lilly and's stronger consensus rating and higher possible upside, equities analysts clearly believe Eli Lilly and is more favorable than Corcept Therapeutics.

Valuation & Earnings

This table compares Eli Lilly and and Corcept Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$22.32 billion7.93$8.32 billion$6.0430.54
Corcept Therapeutics$306.49 million8.68$94.18 million$0.7729.45

Eli Lilly and has higher revenue and earnings than Corcept Therapeutics. Corcept Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eli Lilly and and Corcept Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and24.01%166.45%15.18%
Corcept Therapeutics30.73%25.38%23.16%

Volatility and Risk

Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Summary

Eli Lilly and beats Corcept Therapeutics on 9 of the 14 factors compared between the two stocks.

Corcept Therapeutics (NASDAQ:CORT) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Volatility and Risk

Corcept Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Profitability

This table compares Corcept Therapeutics and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corcept Therapeutics30.73%25.38%23.16%
Bristol-Myers Squibb-0.11%27.48%10.77%

Institutional & Insider Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Corcept Therapeutics and Bristol-Myers Squibb, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corcept Therapeutics01102.50
Bristol-Myers Squibb031012.86

Corcept Therapeutics presently has a consensus price target of $24.00, suggesting a potential upside of 5.82%. Bristol-Myers Squibb has a consensus price target of $74.6429, suggesting a potential upside of 19.22%. Given Bristol-Myers Squibb's stronger consensus rating and higher possible upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Corcept Therapeutics.

Earnings and Valuation

This table compares Corcept Therapeutics and Bristol-Myers Squibb's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$306.49 million8.68$94.18 million$0.7729.45
Bristol-Myers Squibb$26.15 billion5.35$3.44 billion$4.6913.35

Bristol-Myers Squibb has higher revenue and earnings than Corcept Therapeutics. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol-Myers Squibb beats Corcept Therapeutics on 8 of the 15 factors compared between the two stocks.


Corcept Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$161.25-1.1%$424.52 billion$82.06 billion25.35
Pfizer logo
PFE
Pfizer
2.4$36.60-1.7%$204.14 billion$51.75 billion23.61Analyst Report
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$76.31-1.1%$193.09 billion$46.84 billion16.88News Coverage
AbbVie logo
ABBV
AbbVie
2.8$107.54-1.3%$189.79 billion$33.27 billion22.74Analyst Report
Eli Lilly and logo
LLY
Eli Lilly and
2.1$184.49-1.0%$176.92 billion$22.32 billion30.15
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$62.61-1.1%$139.87 billion$26.15 billion-569.13Analyst Upgrade
News Coverage
Zoetis logo
ZTS
Zoetis
2.2$159.85-0.1%$75.93 billion$6.26 billion47.43
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$42.31-0.9%$25.69 billionN/A0.00Analyst Revision
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.48-0.5%$20.50 billion$1.30 billion24.99Analyst Upgrade
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$161.40-0.3%$9.09 billion$2.16 billion50.91Insider Selling
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Omeros logo
OMER
Omeros
1.4$18.23-2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Gap Up
Zogenix logo
ZGNX
Zogenix
1.7$19.27-0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.96-12.7%$373.27 million$16.54 million-3.24High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.55-2.8%$358.06 million$111.39 million25.36News Coverage
Gap Down
Lannett logo
LCI
Lannett
2.0$4.95-1.6%$204.94 million$545.74 million-6.87Analyst Upgrade
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.36-0.5%$166.75 million$15.96 million-2.64Unusual Options Activity
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.17-4.1%$47.30 million$47.53 million-14.41News Coverage
Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.